IPO - REVIVA PHARMACEUTICALS HOLDINGS, INC.

Form Type: 8-K

Filing Date: 2025-06-26

Corporate Action: Ipo

Type: New

Accession Number: 000143774925021361

Filing Summary: On June 26, 2025, Reviva Pharmaceuticals Holdings, Inc. entered into a securities purchase agreement with institutional investors for a registered public offering. The offering involves the sale of 20,000,000 shares of common stock at a public offering price of $0.50 per share, along with Series C and Series D warrants. The Series C Warrants allow for the purchase of up to 20,000,000 shares of common stock and have a five-year term, while the Series D Warrants also permit the purchase of up to 20,000,000 shares but have a term of 12 months. The offering is anticipated to close on or about June 27, 2025, and net proceeds are expected to be approximately $9.0 million, to be utilized for research and development and general corporate purposes. The company has agreed to various restrictions on the further issuance of its common stock following the offering. Additionally, the company entered into a placement agency agreement, paying the agent a fee of 7.0% of the gross proceeds. Forward-looking statements in the filing caution about the risks and uncertainties related to the offering's closing and proceeds.

Form Type: 424B5

Filing Date: 2025-05-30

Corporate Action: Ipo

Type: New

Accession Number: 000143774925019011

Filing Summary: Reviva Pharmaceuticals Holdings, Inc. filed a prospectus supplement to offer common stock amounting to up to $50,000,000. The shares will be sold through a sales agreement with B. Riley Securities, Inc. and A.G.P./Alliance Global Partners as agents. The common stock is traded on Nasdaq under the symbol 'RVPH', and the offering is structured as an at-the-market equity offering, meaning the price will fluctuate based on market conditions. The intended use of proceeds includes funding research and development activities and general corporate purposes. The document also outlines the risks associated with investing in the offered securities, emphasizing that the offering price may exceed the net tangible book value per share. The prospectus provides comprehensive details regarding the stock offering, risk factors, and the company's business operations, with a focus on their lead drug candidate brilaroxazine, currently in development for various neuropsychiatric and respiratory indications.